Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||36.42%||Sales Growth - Q/Q||-25.98%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||47.08%||ROE||51.63%||ROI|
|Current Ratio||8.98||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||82.62%||Net Profit Margin||64.48%||Dividend Payout Ratio|
|Cash From Financing Activities||2.26 M||Cash From Investing Activities||-100.46 M||Cash From Operating Activities||93.25 M||Gross Profit|
|Net Profit||28.75 M||Operating Profit||48.56 M||Total Assets||245.88 M||Total Current Assets||177.78 M|
|Total Current Liabilities||19.79 M||Total Debt||180 K||Total Liabilities||21.67 M||Total Revenue||57.37 M|
|High 52 week||126.37||Low 52 week||65.41||Last close||100.65||Last change||1.01%|
|RSI||77.21||Average true range||5.2||Beta||1.03||Volume||182.38 K|
|Simple moving average 20 days||11.85%||Simple moving average 50 days||26.12%||Simple moving average 200 days||10.71%|
|Performance Week||-2.42%||Performance Month||33.29%||Performance Quart||25.7%||Performance Half||9.94%|
|Performance Year||26.75%||Performance Year-to-date||42.1%||Volatility daily||3.38%||Volatility weekly||7.55%|
|Volatility monthly||15.47%||Volatility yearly||53.58%||Relative Volume||295.56%||Average Volume||290.82 K|
|New High||0.99%||New Low|
2019-03-18 07:30:00 | Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies
2019-03-11 07:30:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
2019-02-15 07:35:00 | Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth
2019-02-06 22:49:54 | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT
2019-02-06 20:43:08 | Enanta Pharmaceuticals Inc ENTA Q1 2019 Earnings Conference Call Transcript
2019-02-06 17:10:10 | Enanta Pharmaceuticals ENTA Lags Q1 Earnings and Revenue Estimates
2019-02-06 16:07:13 | Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot
2019-01-30 10:31:03 | Enanta Pharmaceuticals ENTA Earnings Expected to Grow: Should You Buy?
2019-01-22 12:09:11 | Do You Like Enanta Pharmaceuticals, Inc. NASDAQ:ENTA At This P/E Ratio?
2018-12-20 08:00:00 | Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-15 11:23:55 | Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA
2018-12-05 10:28:44 | Is Enanta Pharmaceuticals Inc’s NASDAQ:ENTA CEO Pay Fair?
2018-11-29 00:11:44 | Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT
2018-11-26 19:34:33 | Enanta Pharmaceuticals Inc ENTA Q4 2018 Earnings Conference Call Transcript
2018-11-26 16:16:57 | Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot
2018-11-19 10:30:03 | Enanta Pharmaceuticals ENTA Expected to Beat Earnings Estimates: Should You Buy?
2018-11-07 10:10:03 | Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals ENTA
2018-10-26 08:15:00 | Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology, Ctrip.com International, and CyberArk Software — Future Expectations, Projections Moving into 2018
2018-10-11 13:31:41 | How Good Is Enanta Pharmaceuticals Inc NASDAQ:ENTA, When It Comes To ROE?
2018-10-05 11:00:00 | Liver Cancers Rising - Stocks to Watch
2018-09-25 08:45:00 | Recent Analysis Shows Enanta Pharmaceuticals, Multi-Color, Otter Tail, Franklin Resources, CubeSmart, and EnPro Industries Market Influences — Renewed Outlook, Key Drivers of Growth
2018-08-27 16:01:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
2018-08-20 17:45:22 | Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT
2018-08-13 06:00:57 | Why Enanta Stock Is Still a Strong Buy With Huge Upside
2018-08-07 17:35:09 | Enanta Pharmaceuticals ENTA Q3 Earnings and Revenues Top Estimates
2018-08-07 16:32:22 | Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot
2018-08-02 10:08:02 | Why Earnings Season Could Be Great for Enanta Pharmaceuticals ENTA
2018-06-27 10:39:02 | Achieve Life Sciences' Shares Rise on Positive Clinical Data
2018-06-15 14:39:50 | 2 Stable and 2 Speculative Biotech Stocks to Buy
2018-06-12 07:30:00 | Enanta Pharmaceuticals Recognizes the 1st International NASH Day
2018-06-01 08:38:12 | Why Enanta Pharmaceuticals ENTA Could Shock the Market Soon
2018-05-29 17:45:09 | Bayer's Generic Competition, Pipeline Setback Issues Remain
2018-05-29 08:10:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — New Research Emphasizes Economic Growth
2018-05-23 15:05:07 | Dr. Reddy's RDY Q4 Earnings Fall, Revenues Decline Y/Y
2018-05-21 14:00:23 | Analysing NVR, DPZ, ENTA And QLYS Stocks
2018-05-21 12:30:02 | Total Returns and Sector Exposure for Growth Indexes—Continued